Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | CTRC | Q99895 | 2/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403541 | 0.98 | ALDH1A1 (0.44) | ALDH1A1CA2SLC2A1PRSS1CTRC | |
| SCHEMBL7572881 | 0.71 | PARP1 (0.53) | ALDH1A1 | |
| SCHEMBL29164113 | 0.70 | — | — | |
| SCHEMBL1362094 | 0.70 | — | — | |
| SCHEMBL17544910 | 0.69 | ALDH1A1 (0.40) | ALDH1A1PRSS1CTRCF2 | |
| SCHEMBL242884 | 0.69 | PRSS1 (0.41) | ALDH1A1SLC2A1PRSS1CTRCF2 | |
| SCHEMBL7662490 | 0.67 | BRD4 (0.39) | ALDH1A1CA2 | |
| SCHEMBL6334691 | 0.67 | MEN1 (0.43) | ALDH1A1CA2 | |
| SCHEMBL23318493 | 0.65 | CA2 (0.33) | CA2 | |
| SCHEMBL1154518 | 0.64 | ALDH1A1 (0.52) | ALDH1A1PRSS1CTRCF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953859-B2 | Production process for 5-alkyl-oxazolidin-2,4-dione | SHOWA DENKO K.K. (JP) | 2005-10-11 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-20030181729-A1 | Production process for 5-alkyl-oxazolidin-2,4-dione | SHOWA DENKO K.K. (JP) | 2003-09-25 | — | — | US | disclosed |
| WO-2002098867-A1 | PRODUCTION PROCESS FOR 5-ALKYL-OXAZOLIDIN-2,4-DIONE | SHOWA DENKO K.K. (JP) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181729-A1 | Production process for 5-alkyl-oxazolidin-2,4-dione | HAAO, HPD, HAO2 | ALDH1A1 72/4885CA2 13/4885SLC2A1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.